Trivant Custom Portfolio Group LLC Buys 199 Shares of Eli Lilly and Company (NYSE:LLY)

Trivant Custom Portfolio Group LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 19.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,242 shares of the company’s stock after acquiring an additional 199 shares during the period. Trivant Custom Portfolio Group LLC’s holdings in Eli Lilly and Company were worth $1,100,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Core Wealth Advisors Inc. raised its position in Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares during the last quarter. Lynx Investment Advisory bought a new stake in shares of Eli Lilly and Company in the second quarter worth $32,000. LGT Financial Advisors LLC acquired a new position in Eli Lilly and Company during the second quarter worth $36,000. Redmont Wealth Advisors LLC bought a new position in Eli Lilly and Company in the first quarter valued at $40,000. Finally, Morton Brown Family Wealth LLC raised its stake in shares of Eli Lilly and Company by 45.5% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after purchasing an additional 15 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded up $1.61 during mid-day trading on Friday, reaching $887.16. 1,971,436 shares of the company were exchanged, compared to its average volume of 3,031,093. The company has a fifty day simple moving average of $900.13 and a 200-day simple moving average of $847.35. The firm has a market cap of $843.16 billion, a PE ratio of 130.66, a PEG ratio of 2.78 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 12 month low of $531.61 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, equities research analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 93,593 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $918.64, for a total value of $85,978,273.52. Following the sale, the insider now directly owns 97,153,810 shares in the company, valued at approximately $89,249,376,018.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on LLY. Citigroup began coverage on shares of Eli Lilly and Company in a research report on Friday, September 13th. They set a “buy” rating and a $1,060.00 price target on the stock. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Bank of America raised their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a research note on Thursday. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $977.35.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.